GMED (Globus Medical) EBIT: $601 Mil (TTM As of Mar. 2026)


GMED Globus Medical Inc GMED
97 GF Score
Price $84.18
GF Value $98.62
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Globus Medical EBIT?

Globus Medical GMED +2.51% 97 EBIT is $601 Mil as of Mar. 2026. GuruFocus rates GMED with a GF Score™ of 97/100 and a GF Value™ of $98.62 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Globus Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $162 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $601 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Globus Medical's annualized ROC % for the quarter that ended in Mar. 2026 was 11.38%. Globus Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 39.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Globus Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.51%.


Globus Medical  (NYSE:GMED) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Globus Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=647.908 * ( 1 - 20.86% )/( (4476.03 + 4535.885)/ 2 )
=512.7543912/4505.9575
=11.38 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5302.761 - 269.488 - ( 557.243 - max(0, 498.499 - 2125.611+557.243))
=4476.03

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5439.555 - 273.819 - ( 629.851 - max(0, 482.463 - 2198.12+629.851))
=4535.885

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Globus Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=647.908/( ( (628.238 + max(1019.88, 0)) + (618.646 + max(1051.921, 0)) )/ 2 )
=647.908/( ( 1648.118 + 1670.567 )/ 2 )
=647.908/1659.3425
=39.05 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(678.938 + 759.277 + 65.426) - (269.488 + 27.655 + 186.618)
=1019.88

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(686.433 + 772.602 + 60.228) - (273.819 + 26.347 + 167.176)
=1051.921

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Globus Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=601.107/10912.357
=5.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Globus Medical EBIT Related Terms


Globus Medical EBIT Historical Data

* Premium members only.

The historical data trend for Globus Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Globus Medical EBIT Chart

Globus Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.86 236.25 201.42 219.39 537.19

Globus Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.06 122.81 135.01 181.31 161.98

GMED vs PODD, PEN, MASI: EBIT Comparison

For the Medical Devices subindustry, Globus Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Globus Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Globus Medical's EV-to-EBIT falls into.


GMED
97GF Score
Globus Medical Inc GMED
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Globus Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $601 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $601 Mil mean?
Globus Medical (GMED) has a EBIT of $601 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Globus Medical.
Is Globus Medical's EBIT too high?
Globus Medical's current EBIT is $601 Mil. Overall, Globus Medical has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's EBIT compare to PODD and PEN?
Globus Medical's EBIT of $601 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Globus Medical. Globus Medical's current EBIT is $601 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.62, compared to a current price of $84.18 — trading 14.6% below its estimated fair value. The current EBIT is $601 Mil. Globus Medical's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Globus Medical (GMED), the current EBIT is $601 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Globus Medical (GMED) Overvalued in 2026?

Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued. The current stock price of $84.18 is trading 14.6% below its estimated GF Value™ of $98.62. GuruFocus considers Globus Medical to be Modestly Undervalued.

Key valuation signals for GMED:

  • EBIT: $601 Mil
  • GF Value™: $98.62 vs. price of $84.18 (14.6% below fair value)
  • GF Score™: 97/100 with 4 warning signs

No single metric tells the full story. See the GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Globus Medical Business Description

Other Exchanges GMED:MexicoGM0N:Germany
Address 2560 General Armistead Avenue, Audubon, PA, USA, 19403
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
97GF Score

Get the complete analysis for GMED

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$84.18
Price
$98.62
GF Value